Kalaris Therapeutics, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Liisa Bayko appointed Chief Financial Officer effective July 20, 2026, with annualized base salary of $475,000, target annual bonus up to 40% of base salary, and option grant of 220,000 shares vesting over 4 years at fair market value. Agreement includes severance benefits of 9 months base salary plus COBRA coverage if terminated without cause outside a change-of-control window, or 12 months base salary plus 100% target bonus if terminated without cause within 3 months before or 12 months after a change of control, subject to execution of release agreement.
Why this rating
CFO hire is routine for small biotech. Compensation ($475K base) is ~3.8% of $12.6M market cap—material but expected for executive role. No transformational event.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.